Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck Sharpe and Dohme details new restructuring programme

Merck Sharpe and Dohme details new restructuring programme

9th July 2010

Merck Sharpe and Dohme has announced plans to restructure its research and manufacturing activities in a new global initiative.

The pharmaceutical company is looking to consolidate certain business operations and phase out a number of sites in order to improve the efficiency and flexibility of its operations.

It represents the latest phase of a wider worldwide reorganisation programme which commenced with the merger with Schering-Plough in November 2009.

Merck Sharpe and Dohme expects that its restructuring activities thus far will help save the company as much as $3.1 billion (two billion pounds), as well as positioning the firm to focus on key areas such as biologics, vaccines and emerging markets.

Richard Clark, chairman and chief executive officer of Merck Sharpe and Dohme, said: “These changes are crucial to drive future growth and realise the promise of being a global healthcare leader for the long term.”

Last month, the company published new data from a clinical trial of the type 2 diabetes drug Janumet, which illustrated its potential benefits when compared to pioglitazone.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.